VivoSeq
Neurology

Tic Disorder

70

Pipeline Programs↗

12

Active Trials↗

32

Companies Involved↗

Tic Disorder is a moderately active landscape with 70 programs across 32 companies. The most active players are Scioto Biosciences, Inc., Mononuclear Therapeutics Ltd., Roche. 13 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

65/100

Pipeline Velocity

0/100

Mech. Concentration

3/100

Completion Rate

83/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Scioto Biosciences, Inc.

1 program

Phase 1M

Mononuclear Therapeutics Ltd.

1 program

Phase 1Roche logo

Roche

3 programs

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 2Sanofi logo

Sanofi

2 programs

Phase 2Bayer logo

Bayer

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical14

Amoxicillin

Global Antibiotics Research and Development Partnership

Cyclophosphamide

Baxter Healthcare Corporation

Methotrexate

Alnylam Pharmaceuticals

Etoposide

Avyxa

Filgrastim

Eastern Cooperative Oncology Group

Phase 14

Intranasal Oxytocin

University of Electronic Science and Technology of China

Apixaban

Bristol-Myers Squibb

D-Cycloserine

Massachusetts General Hospital

SB-121

Scioto Biosciences, Inc.

Phase 234

Olaparib

AstraZeneca

Larotrectinib

Bayer

Selpercatinib

Eli Lilly

Erdafitinib

Johnson & Johnson

Palbociclib

Pfizer

Phase 35

Aripiprazole

Otsuka

Buspirone

Bristol-Myers Squibb

Haloperidol Decanoate

Wim Janssens

Tiapride

Tasly Pharmaceuticals, Inc.

Ricrolin+

Icahn School of Medicine at Mount Sinai

Approved13

Olanzapine

MODAG GmbH

Prednisolone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Duloxetine

Alnylam Pharmaceuticals

Guanfacine

Promius Pharma, LLC

Ondansetron

Novartis

Analysis

Modality Breakdown

96%

Small molecule

68 of 71 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody23%Protein / enzyme11%

Small molecule leads; the ring shows all 71 classified programs, each share of the total. Modality classified for 100% of 72 pipeline programs.

Analysis

Trial Status

65

clinical trials

Completed40 · 62%
Active, not recruiting6 · 9%
Terminated5 · 8%
Unknown status5 · 8%
Recruiting4 · 6%
Withdrawn3 · 5%
Other2 · 3%

Clinical Trials

Trial Activity

65 trials

A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults
Recruiting·—·Phase 2·NCT05622201·120 enrolled
Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder
Recruiting·—·Phase 4·NCT06232473·424 enrolled
Mirdametinib in Histiocytic Disorders
Recruiting·—·Phase 2·NCT06153173·40 enrolled
Magnetic Seizure Therapy for Psychotic Disorders
Recruiting·SShanghai Jiao Tong University School of Medicine·N/A·NCT06581302·50 enrolled
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03210714·20 enrolled
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03698994·20 enrolled
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04320888·1 enrolled
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03213704·9 enrolled
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04284774·5 enrolled
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03155620·1,376 enrolled
Stellate Ganglion Block in Children With Autistic Disorder
Not yet recruiting·—·N/A·NCT06319599·80 enrolled
Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Enrolling by invitation·TThe University of Texas Health Science Center, Houston·N/A·NCT00833599·283 enrolled
Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders
Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT02930005·8 enrolled
Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder
Completed·—·Phase 2/3·NCT00873509·166 enrolled
28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder
Completed·SScioto Biosciences, Inc.·Phase 1·NCT04944901·15 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)